仁度生物: 2025年半年度报告摘要

Company Overview - Shanghai Rendu Biotechnology Co., Ltd. is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board with the stock code 688193 [2] - The company reported total assets of approximately 984.94 million yuan at the end of the reporting period, a decrease of 0.95% compared to the previous year [2] - The net assets attributable to shareholders of the listed company were not specified in the provided data [2] Financial Performance - The company's operating revenue for the reporting period was approximately 81.24 million yuan, reflecting a decline of 6.27% compared to the same period last year [2] - The total profit for the period was approximately 764.38 thousand yuan, a significant decrease of 79.97% year-on-year [2] - The net profit attributable to shareholders of the listed company was reported as -4.28 million yuan, indicating a substantial loss compared to a profit of -143.37 thousand yuan in the previous year [2] - The net cash flow from operating activities was -1.04 million yuan, a decrease of 109.96% compared to the previous year [2] Shareholder Information - As of the reporting period, the total number of shareholders was 3,495 [3] - The largest shareholder, residing overseas, holds 19.65% of the shares, amounting to 7.86 million shares [3] - The second-largest shareholder, also overseas, holds 15.44% of the shares, totaling 6.18 million shares [3] Important Events - The report indicates that there were no significant changes in the company's operating conditions during the reporting period [5]